-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Short Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Short Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Short Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewNet Present Value Model: 9 Meters Biopharma Inc’s Vurolenatide
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewNet Present Value Model: Avidity Biosciences Inc’s AOC-1020
Empower your strategies with our Net Present Value Model: Avidity Biosciences Inc's AOC-1020 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pollinex Quattro Grass in Allergic Rhino-Conjunctivitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pollinex Quattro Grass in Allergic Rhino-Conjunctivitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pollinex Quattro Grass in Allergic Rhino-Conjunctivitis Drug Details: Pollinex...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vurolenatide in Short Bowel Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vurolenatide in Short Bowel Syndrome Drug Details: NB-1001 (XTEN-GLP1)Â was under development for the treatment of...
-
Product Insights
Insulin Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Insulin Delivery Pipeline Market Report Overview Insulin delivery devices are used to inject measured doses of insulin through the skin and into the fatty tissues below. Insulin delivery devices include Insulin pens and Insulin pumps. The insulin delivery pipeline market research report provides comprehensive information about the Insulin delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Insulin Pumps ·      Patch...
-
Product Insights
Celiac Disease Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Celiac Disease Clinical Trials Market Report Overview The Celiac Disease clinical trial market research report provides an overview of the Celiac Disease Clinical trials scenario. This report provides top-line data relating to the clinical trials on Celiac Disease and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type....
-
Company Profile
9 Meters Biopharma Inc – Company Profile
9 Meters Biopharma Inc (9 Meters Biopharma) is a clinical-stage biopharmaceutical company developing novel medicines for autoimmune and inflammatory diseases. The company’s pipeline products include Larazotide, an orally administered, gut-restricted tight-junction regulator for celiac disease and NM-003, a long-acting GLP-2 analog, under orphan indication selection. The company focuses on rare or debilitating digestive diseases with the potential to transform current treatment paradigms for patients and address unmet medical needs. 9 Meters Biopharma is headquartered in Raleigh, North Carolina, the US.
Add to Basket